News
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...
4d
Zacks.com on MSNVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowZacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...
Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 ...
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.
Analyst Ratings Published 06/17/2025, 11:02 AM 0 Vertex stock price target lowered to $420 on slower Alyftrek uptake VRTX 0.57% ...
17d
Zacks Investment Research on MSNVertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItVertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
The stock's fall snapped a three-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results